Blood neurofilament light as a potential endpoint in Phase 2 studies in MS

Blood neurofilament light chain as a biomarker of MS disease activity and treatment response

(2019) Jens Kuhle et al.   NEUROLOGY

Serum neurofilament as a predictor of disease worsening and brain and spinal cord atrophy in multiple sclerosis

(2018) Christian Barro et al.   BRAIN

Serum neurofilament light chain is a biomarker of acute and chronic neuronal damage in early multiple sclerosis

(2018) Nelly Siller et al.   Multiple Sclerosis Journal

Serum neurofilament light chain is a biomarker of acute and chronic neuronal damage in early multiple sclerosis

(2018) Nelly Siller et al.   Multiple Sclerosis Journal

Neurofilaments as biomarkers in neurological disorders

(2018) Michael Khalil et al.   Nature Reviews Neurology

Neurofilament light chain serum levels correlate with 10‐year MRI outcomes in multiple sclerosis

(2018) Tanuja Chitnis et al.   Annals of Clinical and Translational Neurology

Plasma neurofilament light chain levels in patients with MS switching from injectable therapies to fingolimod

(2017) Fredrik Piehl et al.   Multiple Sclerosis Journal

Serum neurofilament is associated with progression of brain atrophy and disability in early MS

(2017) Jens Kuhle et al.   NEUROLOGY

Monitoring disease activity in multiple sclerosis using serum neurofilament light protein

(2017) Lenka Novakova et al.   NEUROLOGY

Plasma neurofilament light chain levels in patients with MS switching from injectable therapies to fingolimod

(2017) Fredrik Piehl et al.   Multiple Sclerosis Journal

Cerebrospinal fluid levels of neurofilament and tau correlate with brain atrophy in natalizumab-treated multiple sclerosis

(2016) J. Mellergård et al.   EUROPEAN JOURNAL OF NEUROLOGY

Serum neurofilament light chain in early relapsing remitting MS is increased and correlates with CSF levels and with MRI measures of disease severity

(2016) Jens Kuhle et al.   Multiple Sclerosis Journal

Reduced inflammation in relapsing-remitting multiple sclerosis after therapy switch to rituximab

(2016) Pierre de Flon et al.   NEUROLOGY

Serum neurofilament light chain in early relapsing remitting MS is increased and correlates with CSF levels and with MRI measures of disease severity

(2016) Jens Kuhle et al.   Multiple Sclerosis Journal

Fingolimod and CSF neurofilament light chain levels in relapsing-remitting multiple sclerosis

(2015) J. Kuhle et al.   NEUROLOGY

Neurofilament light and heavy subunits compared as therapeutic biomarkers in multiple sclerosis

(2013) J. Kuhle et al.   ACTA NEUROLOGICA SCANDINAVICA

MRI lesions as a surrogate for relapses in multiple sclerosis: a meta-analysis of randomised trials

(2013) Maria Pia Sormani et al.   LANCET NEUROLOGY

Body fluid biomarkers in multiple sclerosis

(2013) Manuel Comabella et al.   LANCET NEUROLOGY

A comparative study of CSF neurofilament light and heavy chain protein in MS

(2013) Jens Kuhle et al.   Multiple Sclerosis Journal

Neurofilaments as biomarkers in multiple sclerosis

(2012) Charlotte E Teunissen et al.   Multiple Sclerosis Journal

Clinico-pathological evidence that axonal loss underlies disability in progressive multiple sclerosis

(2010) Emma C Tallantyre et al.   Multiple Sclerosis Journal

A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis

(2010) Ludwig Kappos et al.   NEW ENGLAND JOURNAL OF MEDICINE

Magnetic resonance imaging as a potential surrogate for relapses in multiple sclerosis: A meta-analytic approach

(2009) Maria Pia Sormani et al.   ANNALS OF NEUROLOGY